SoftServe Gen AI Drug Discovery Solution

WHAT WE DO:

• The complexity and resource intensity of drug discovery processes often lead to high costs, extended timelines, and a low success rate. This challenge is particularly significant in early-stage drug discovery, where identifying successful drug candidates is critical but highly uncertain.

• SoftServe Gen AI Drug Discovery Solution, deployed on AWS and accelerated by NVIDIA BioNeMo Blueprints, provides an innovative approach to streamline these processes. Leveraging AI-driven molecule generation and screening allows researchers, application developers, pharmaceutical companies, and AI pharma discovery teams to generate novel drug candidates. Integrating NVIDIA’s tools and AWS Services provides state-of-the-art AI models and significantly speeds up this process, seamlessly connecting every step of molecular screening. That reduces research and development costs, boosts efficiency in early-stage drug production, and creates new revenue opportunities.

WHAT YOU GET:

• REDUCE COST IN EARLY-STAGE DRUG DISCOVERY

CATEGORIES:

SoftServe Gen AI Drug Discovery Solution enhances functionality and scalability by integrating NVIDIA BioNeMo Blueprints and AWS services, offering a reliable AI-driven approach to drug discovery.

• NVIDIA BioNeMo™ Blueprints handle tasks such as molecule generation and property prediction, enabling researchers to rapidly explore chemical space.

• AWS S3 provides scalable and secure storage for research data, supporting large datasets essential for AI-powered drug discovery.

Target Industry:

• Healthcare and Life Sciences

FEATURES / BENEFITS:

• AI-Powered Drug Discovery Enhanced by NVIDIA BioNeMo Blueprints and AWS Integration:

The SoftServe Gen AI Drug Discovery Solution combines the advanced capabilities of NVIDIA BioNeMo Blueprints with AWS's scalability and robustness. This solution utilizes powerful molecular generation and prediction models, seamlessly accessing and analyzing molecular data to streamline the drug discovery process.

• Advanced Molecular Property Prediction:

SoftServe’s AI-driven models predict key molecular properties, also enabling researchers to assess drug-likeness, efficacy, and safety. This predictive capability reduces the time spent on manual analysis and optimizes the candidate selection process, focusing efforts on the most promising compounds for lab testing.

**Technology used **

• NVIDIA NIM

• NVIDIA BioNeMo

• NVIDIA TensorRT

• NVIDIA NeMo

• Amazon S3

Use Cases:

• Generation of Novel Molecular Compounds

• Protein Structure Prediction

• Molecular Docking and ADME-TOX Predictions